TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Inspiremd, Inc.
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

InspireMD announced that its C-GUARDIANS pivotal trial results have been published in JACC, demonstrating that the CGuard® Prime Carotid Stent System achieved the lowest 30-day and 1-year major adverse event rates in carotid stenting studies, with a 30-day DSMI rate of 0.95% and 1-year ipsilateral stroke rate of 1.93%. The trial enrolled 316 patients including 25% symptomatic cases, showing strong safety and efficacy data for carotid artery stenosis treatment.

Insights
STZ   positive

Down 40% in 2025 but with significant analyst price target upside, low forward earnings multiple, and diverse beverage portfolio


NSPR   positive

The company announced positive pivotal trial results published in a top-tier medical journal (JACC), demonstrating superior safety outcomes (lowest event rates in the industry) for its flagship product CGuard® Prime. The publication in a prestigious journal and achievement of primary endpoints with historically low complication rates represent significant validation and should support future adoption and revenue growth.